Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant <scp> <i>Pseudomonas aeruginosa</i> </scp> infections in cancer patients-Reference-Cited by-同舟云学术

Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients

Published:2022-12-08 Issue:4 Volume:89 Page:1452-1461
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Zavrelova Alzbeta¹,Sima Martin²^ORCID,Malakova Jana³,Rozsivalova Petra⁴,Paterova Pavla⁵,Zak Pavel¹,Visek Benjamin¹,Michalickova Danica²,Slanar Ondrej²,Radocha Jakub¹

Affiliation:

1. 4th Department of Internal Medicine – Hematology University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University Hradec Kralove Czech Republic

2. Department of Pharmacology, First Faculty of Medicine Charles University and General University Hospital in Prague Prague Czech Republic

3. Institute of Clinical Biochemistry University Hospital Hradec Kralove and Charles University in Prague, Faculty of Medicine in Hradec Kralove Hradec Kralove Czech Republic

4. Department of Clinical Pharmacy, Hospital Pharmacy Faculty of Pharmacy in Hradec Kralove, Charles University and University Hospital Hradec Kralove Hradec Kralove Czech Republic

5. Department of Clinical Microbiology University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University Hradec Kralove Czech Republic

Funder

Univerzita Karlova v Praze

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15612

Reference30 articles.

1. Cephalosporin-Induced Neurotoxicity: Clinical Manifestations, Potential Pathogenic Mechanisms, and the Role of Electroencephalographic Monitoring

2. Probable Nonconvulsive Status Epilepticus With the Use of High-Dose Continuous Infusion Ceftazidime

3. State Institute for Drug Control of Czech Republic.Summary of product characteristics (ceftazidime). Updated December 20 2021. Accessed August 25 2022.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostatic Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime: Dosing Strategy for Bacterial Prostatitis;The Journal of Clinical Pharmacology;2024-08-26

2. Adequacy of the Dosing and Infusion Time of Ceftazidime/Avibactam for the Treatment of Gram-Negative Bacterial Infections: A PK/PD Simulation Study;Infection and Drug Resistance;2024-07

3. Ceftazidime-related neurotoxicity in a patient with renal impairment: a case report and literature review;Infection;2024-02-02

4. Amikacin/ceftazidime/colistin;Reactions Weekly;2023-11-11